Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat in CKD and Heart Failure
NCT07047547Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jun 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Vericiguat oral suspension (Formulation 4) in heart failure (HF), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Left Ventricular Ejection Fraction at 12 weeks. Started Jun 2025; status: recruiting.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT07047547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07047547.